AI Summary
This article discusses the extended 8-year follow-up results of the phase III CheckMate 214 trial, comparing the efficacy and safety of nivolumab plus ipilimumab versus sunitinib for the first-line treatment of advanced renal cell carcinoma. The study shows that nivolumab+ipilimumab has superior overall survival and durable response benefits compared to sunitinib in patients with aRCC.
Nivolumab+ipilimumab (NIVO+IPI) has demonstrated superior overall survival (OS) and durable response benefits versus sunitinib (SUN) with long-term follow-up in patients with advanced renal cell carcinoma (aRCC). We report updated analyses with 8 years median follow-up from CheckMate 214.